Amneal Pharmaceuticals, Inc. (AMRX) intrinsic value & 10-year financials
Amneal Pharmaceuticals, Inc. (AMRX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 12.8% a year to $3.0B, with an average return on invested capital of 4.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $19.18
- Market cap
- $6.2B
- Revenue (FY2025)
- $3.0B
- Revenue growth (10-yr CAGR)
- 12.8%
- ROIC (10-yr avg)
- 4.3%
- Free cash flow (FY2025)
- $269.9M
AMRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.0B | $72.1M | $0.22 | $269.9M | 13.1% | 15.5% |
| FY2024 | $2.8B | -$116.9M | -$0.38 | $243.2M | 8.9% | 11.0% |
| FY2023 | $2.4B | -$79.3M | -$0.48 | $302.4M | 8.5% | 7.8% |
| FY2022 | $2.2B | -$270.6M | -$0.86 | $18.7M | -4.3% | -3.3% |
| FY2021 | $2.1B | $13.2M | $0.07 | $194.1M | 7.3% | 3.0% |
| FY2020 | $2.0B | $91.1M | $0.61 | $322.6M | 4.6% | 1.7% |
| FY2019 | $1.6B | -$361.9M | -$2.74 | -$45.5M | -15.3% | -4.4% |
| FY2018 | $1.7B | -$19.7M | -$0.16 | $167.1M | -1.2% | -0.8% |
| FY2017 | $1.0B | $0 | — | $139.4M | 23.7% | 8.3% |
| FY2016 | $1.0B | $0 | — | -$7.7M | 28.0% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Amneal Pharmaceuticals, Inc. is a consistent compounder, expanding top-line revenue at 12.8% annually over the past decade.
Amneal Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just 4.3% ROIC.
Amneal Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Amneal Pharmaceuticals, Inc. is modeled at -18.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-5.39 per share.